New pill targets common cancer driver in advanced tumors
NCT ID NCT06585488
First seen Sep 30, 2025 · Last updated May 13, 2026 · Updated 35 times
Summary
This early-phase study tests a new experimental drug called BGB-53038 in people with advanced or metastatic solid tumors that have a specific genetic change (KRAS mutation or amplification). The drug is a pan-KRAS inhibitor, meaning it aims to block many forms of the faulty KRAS protein that helps cancers grow. The study will first find a safe dose, then test the drug alone or with other treatments in up to 514 participants with lung, colorectal, pancreatic, stomach, or esophageal cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSongpaGu, Seoul Teugbyeolsi, 05505, South Korea
-
Auckland City Hospital
RECRUITINGAuckland, 1023, New Zealand
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Blacktown Cancer and Haematology Centre
RECRUITINGBlacktown, New South Wales, NSW 2148, Australia
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, WA 6009, Australia
-
Monash Health
RECRUITINGClayton, Victoria, VIC 3168, Australia
-
Peter Maccallum Cancer Centre
RECRUITINGMelbourne, Victoria, VIC 3000, Australia
-
Samsung Medical Center
RECRUITINGGangnamGu, Seoul Teugbyeolsi, 06351, South Korea
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, Gyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, Seoul Teugbyeolsi, 03080, South Korea
-
Severance Hospital Yonsei University Health System
RECRUITINGSeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea
-
Shanxi Provincial Cancer Hospital
RECRUITINGTaiyuan, Shanxi, 030013, China
-
Sidney Kimmel Comprehensive Cancer At Johns Hopkins
RECRUITINGBaltimore, Maryland, 21287, United States
-
The University of Texas Md Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4009, United States
-
University of Kansas Medical Center Research Institute
RECRUITINGKansas City, Kansas, 66160-8500, United States
-
Usc Norris Comprehensive Cancer Center (Nccc)
RECRUITINGLos Angeles, California, 90089-1019, United States
Conditions
Explore the condition pages connected to this study.